Tandem Diabetes Care Inc. (TNDM)
NASDAQ: TNDMHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TNDM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.22B
- Forward P/E
- 195.48
- EPS (TTM)
- -$0.70
- Dividend yield
- None
- 52-week range
- 12.26 – 29.65
- Day range
- 16.51 – 17.86
- Volume / Avg
- 2.67M / 2.26M
- Beta
- —
- Shares outstanding
- 69.79M
52-week range
TNDM stock today
Shares of Tandem Diabetes Care (TNDM) finished higher on Nov 20 at $17.46, a gain of 3.93% or $0.66 per share, versus the S&P 500's 3.70% decline. Shares are 41.1% below their 52-week high of $29.65, set on Feb 24, 2026 and 42.4% above the 52-week low of $12.26, in the middle of the past year's range. TNDM is down 20.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.0%.
Tandem Diabetes Care has posted a net loss over the last twelve months (EPS of -$0.70), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tandem Diabetes Care
Company profileTandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. John F. Sheridan
- Headquarters
- San Diego, CA
- Employees
- 2,500
- IPO year
- 2013
- Website
- tandemdiabetes.com
Financial highlights
Full financialsIn fiscal 2025, Tandem Diabetes Care generated $1.01 billion in revenue, up 7.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Tandem Diabetes Care reported a net loss of $204.7 million, compared with a loss of $96.0 million a year earlier. Gross margin was 53.8% (up from 52.1%) and operating margin -18.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.01B | $940.20M | $747.72M | $801.22M | $702.80M |
| Growth | +7.93% | +25.74% | -6.68% | +14.00% | +40.89% |
| Net income | $-204.71M | $-96.03M | $-222.61M | $-94.59M | $15.57M |
| EPS (diluted) | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 |
Analyst forecast
ForecastConsensus (25 analysts)
buy
Avg. price target
$27.10+55.21%
- Strong buy 2
- Buy 12
- Hold 11
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.10 vs $-0.27
- Surprise
- +62.96%
TNDM news
All TNDM news- Stocks Pressured by Renewed Weakness in ChipmakersNasdaqMPC, SNDK, HL, CDE
- Stocks Mixed as Nvidia Erases Overnight GainsNasdaqALK, MPC, HL, CDE
- Why is Tandem Diabetes Care stock rallying today?Investing.com
- Tandem Diabetes Care jumps 12% on FDA clearance for tubeless MobiSeeking Alpha
- Tandem (TNDM) Q3 2026 Earnings Call TranscriptNasdaq
- Tandem Diabetes Care GAAP EPS of -$0.10 beats by $0.15, revenue of $283.7M beats by $17.85MSeeking Alpha
- Tandem Diabetes Care appoints Jeannette Bankes as CEOSeeking Alpha
- Tandem Diabetes Care Announces Third Quarter 2026 Financial ResultsBusiness Wire
Tandem Diabetes Care peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVCRNovoCure Limited | 10.71 | +0.19% | $1.25B | vs TNDM |
| DRTSAlpha Tau Medical Ltd. | 11.76 | +3.93% | $1.09B | vs TNDM |
| SIBNSI-BONE Inc. | 23.73 | -0.08% | $1.07B | vs TNDM |
| IRMDiRadimed Corporation | 81.02 | -0.30% | $1.04B | vs TNDM |
| IARTIntegra LifeSciences Holdings Corporation | 13.25 | -2.21% | $1.03B | vs TNDM |
| ATECAlphatec Holdings Inc. | 6.68 | -3.19% | $1.02B | vs TNDM |
| SGPSpyGlass Pharma Inc. | 30.43 | -1.14% | $1.02B | vs TNDM |
| PRCTPROCEPT BioRobotics Corporation | 24.70 | -4.08% | $1.42B | vs TNDM |
Indexes, lists and sector
Tandem Diabetes Care stock FAQ
What is Tandem Diabetes Care's stock price today?
TNDM last traded at $17.46 as of Nov 20, 4:00 PM EST, up 3.93% on the day. Prices are delayed at least 15 minutes.
Does Tandem Diabetes Care pay a dividend?
No. Tandem Diabetes Care does not currently pay a regular cash dividend.
Who is Tandem Diabetes Care's CEO?
Mr. John F. Sheridan is the chief executive officer of Tandem Diabetes Care Inc., which has about 2,500 employees.
Has TNDM ever split its stock?
Yes. The most recent TNDM stock split was a 1-for-10 split on Oct 10, 2017.
What is the TNDM 52-week high?
The 52-week high for TNDM is $29.65 and the 52-week low is $12.26. The stock is currently 41.1% below its high.